SK bioscience administers various forms of ethics training for all employees (including part-time) and contractors, to ensure comprehensive understanding and adherence to the Code of Ethics. SK Group's online training targets unethical practices such as budget misallocation, acceptance of monetary/gift incentives, abuse of authority, and workplace harassment, enhancing ethical decision-making and competencies across the workforce. Furthermore, the Company implements regular compliance training for the sales and marketing divisions and delivers ad-hoc training during the onboarding of new and experienced staff to fortify a robust internal compliance culture.

In 2023, SK bioscience executed company-wide ethics management training, facilitated discussion-based ethics practice workshops, and conducted regular/ad-hoc compliance training for the sales and marketing divisions. Additionally, to elevate employees’ ethical decision-making competencies, the Company implemented supplementary internal ethics management training for all staff.

SK bioscience operates a compliance risk management system based on the belief that a company’s competitiveness can only be proven when it secures a competitive advantage in the market while adhering to laws and regulations. In addition, we practice business ethics and compliance management by implementing our Prevent-Detect-Respond framework. This approach helps us avoid profits from unethical business practices and lays the foundation for a fairer and more transparent company.

We established compliance regulations and regularly conduct annual business ethics and compliance training and pledges to prevent risks and embed ethical practices in our employees. Additionally, we operate a monitoring system that continuously checks reporting channels and marketing cost execution. We conduct business ethics practice surveys to evaluate the level of ethical practices, and the results are reflected to improve the compliance management system.

In addition, we have a policy of conducting audits of our ethical and anti-corruption standards across all operations twice a year. To accomplish this, we established audit compliance regulations and secured specialized audit personnel to ensure independent audits in 2022. Building on this foundation, we conducted regular audits focusing on cost and procurement areas twice, reporting the findings to the Audit Committee in 2023. Additionally, the audits identified and remediate management inefficiencies. We plan to continue auditing key vulnerable areas to drive ongoing improvements.

If violations are identified during investigations and monitoring, we follow disciplinary procedures, notify all employees, and incorporate these findings into our regulations and training programs.

SK bioscience has established a company-wide compliance management system and operates related programs. The Head of Legal & Patent Office is appointed as the Compliance Officer, responsible for planning, implementation, evaluation, and supervision of the entire process of the voluntary compliance program. In addition, the Compliance Officer oversees business-related activities such as pharmaceutical compliance activities and programs to raise the level of awareness of voluntary fair trade compliance among all employees. The Compliance Officer reports annually to the Board on these activities and future plans.

We operate a dedicated compliance division(Ethics Management Team) to establish a compliance system, monitor and investigate reports. The team also makes efforts to prevent compliance violations in advance by providing compliance-related training and imposing penalties for violations. In addition, in order to review the internal business system as the Company's business environment changes, we secured specialized audit personnel and added audit functions to the Ethics Management Team in 2022 to establish audit system. Since 2023, we have made every effort to upgrade the compliance management system throughout the Company by conducting full-scale audit activities.

SK bioscience appoints the Head of Legal & Patent Office as the Compliance Officer to carry out compliance activities. The Compliance Officer is appointed for a term of three years and plays a key role in overseeing the Company’s compliance work to strengthen the governance system, proactively preventing and managing legal risks.

SK bioscience has strengthened its compliance system by specifying the activities, rights, and duties of the Compliance Officer in the Compliance Guidelines. The Compliance Officer is responsible for operating compliance education/training programs and checking whether the Guidelines are being followed. When necessary, the Compliance Officer may request employees to submit materials and seek advice from external experts, as well as make a statement to the Board in relation to compliance control. Beyond general compliance activities, the Compliance Officer actively works to enhance the Company-wide compliance system through risk prevention activities, thereby contributing to the Legal & Patent Office’s 2030 long-term vision of becoming a ‘Proactive & Business-oriented Legal Solution Provider’.

• 거버넌스 체계 정비

  이사회 중심 경영 정착

  이사회 프로세스 정착 및 산하 위원회 운영 지원

  관련 규제 〮 법령에 부합하는 운영체계 수립

  공시 의무, 자본시장법상 규제 준수, ESG 평가 대비

• 선제적 리스크 관리

  전사적/통합적 리스크 관리 체계 구축

  리스크 식별, 평가, 대응, 점검

  계약상 리스크 최소화

  분쟁 및 당사 리스크를 최소화하기 위한 계약 검토

• 국내외 사업 및 프로젝트 지원

  국내외 사업

  국내 마케팅 협약(Alliance) 규제 및 정책 모니터링, 대응

  프로젝트

  C(D)MO, 국내 유통 계약 시 당사의 책임 및 면책 범위 명확화

SK bioscience operates the Audit Committee under the Board to strengthen the audit function and enhance management transparency. The Audit Committee audits the Company’s accounting and finance as well as its overall business in accordance with laws and regulations. It also receives reports on the operation status of the Company’s compliance program and internal accounting management system from the dedicated teams in compliance and reviews their appropriateness. In accordance with the Committee Regulations specified in the Commercial Act, the Audit Committee is composed entirely of outside directors and includes one expert in accounting and finance. Our Audit Committee fulfills its responsibilities and duties to establish more professional and transparent governance.

SK bioscience operates the Internal Accounting Control System(IACS) in accordance with the External Audit Act. As the IACS auditor certification level was raised from review to audit following the IPO in 2021, so we upgraded the IACS to reinforce transparency in corporate accounting and management.

SK bioscience operates the IACS to prepare and disclose reliable accounting information, not to merely maintain a system to comply with legal requirements. To operate the IACS, we established relevant regulations and guidelines and assigned our IACS Part to conduct design and operation evaluation to check all aspects of internal control. Through these procedures, we examine the approval process of major sales, production, financing, and accounting that affect corporate financial statements. Additionally, we effectively respond to external factors that may affect the business, such as changes in accounting standards.

SK bioscience conducts reporting and disclosures related to its internal accounting management system. CEO reports relevant matters to the Annual General Meeting, the Board, and the Audit Committee for each business year. External auditors independently audit the Company's internal accounting management system and report their findings to the Audit Committee. The Committee then independently evaluates the operation of the internal accounting system and reports the results to the Board. Subsequently, in accordance with legal requirements, the results of the internal accounting management system's operation are disclosed publicly. We also provide IACS training to employees and the audit committee to strengthen internal control and improve awareness at the Company level.